Drug Database
ET

ethyl icosapentate (MND2119 / MND 2119 / icosapent, Mochida)

✓ Approved

Sumitomo Pharma Co., Ltd. · Small Molecule · Small Molecule

What is ethyl icosapentate?

ethyl icosapentate is a small molecule developed by Sumitomo Pharma Co., Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesMND2119, MND 2119, icosapent, Mochida
CompanySumitomo Pharma Co., Ltd.
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Sumitomo Pharma Co., Ltd.

Therapeutic Indications

ethyl icosapentate is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Metabolism and nutrition disordersHyperlipidaemia✓ Approved
Metabolism and nutrition disordersHypertriglyceridaemiaPhase III

Related Research Articles

PubMedActa medica Philippina2026-08-30

Use of Non-medical-grade Ethyl Cyanoacrylate for Temporary Skin Closure in a Bleeding Upper Eyelid Arteriovenous Malformation: A Case Report.

Pe Yan Mary Rose MR, Alhasan Yasser E YE, Lumba Gerald Jan M GJM

Cutaneous arteriovenous malformations (AVMs) of the eyelid and orbit are rare vascular anomalies that can present with recurrent or spontaneous bleeding, particularly when the overlying skin is thinned. While definitive management involves embolization and surgical excision, achieving rapid hemostasis can be challenging in resource-limited or outpatient settings. This case report aims to describe the emergency use of non-medical-grade ethyl cyanoacrylate (CA) to achieve temporary hemostasis in an upper eyelid AVM when standard medical materials were unavailable, and to discuss its safety, limitations, and ethical considerations in resource-constrained circumstances. A 23-year-old male with a known right upper eyelid and orbital AVM, scheduled for preoperative embolization, presented with a one-week history of recurrent, profuse bleeding from a superficial skin defect overlying the lesion. Each prior bleeding episode had been controlled with approximately five minutes of firm pressure. On the day of emergency consultation, however, the patient experienced continuous bleeding that persisted despite several hours of pressure dressing. As an immediate hemostatic measure, a thin layer of non-medical-grade ethyl CA was applied to the bleeding surface, resulting in prompt cessation of hemorrhage with only minimal oozing afterward. The wound subsequently healed without secondary infection, tissue necrosis, or other complications. This case demonstrates that non-medical-grade ethyl CA may serve as a temporary hemostatic adjunct for superficial bleeding in select, resource-constrained situations involving eyelid AVMs. While potentially useful in emergencies, its application must remain cautious, limited, and followed by definitive nidus-directed management. Further reports are needed to clarify safety and standardized guidance for its emergency use.

PMID 42668783
Read full article →
PubMedMolecular therapy. Oncology2026-08-30

StagX1, an isoquinolinone compound, selectively targets CES1-positive Ewing sarcoma cells as a potential therapeutic agent.

Zhang Nenggang N, Gilbertson Scott R SR, Li Feng F, Pati Debananda D

StagX1 {ethyl 2-[[2-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]-2-oxoethyl]-1,2-dihydro-1-oxo-5-isoquinolinyl]oxy]propanoate} is a derivative of isoquinolinone, possessing an ethyl propionate. StagX1 exhibits growth-inhibitory activity in multiple Ewing sarcoma cell lines. To advance StagX1 as a potential lead, we conducted experiments to examine its metabolism and stability in tissue culture media, plasma, liver microsomes, cells and mice. Our studies demonstrate that StagX1 is metabolically unstable and undergoes rapid hydrolysis to its corresponding acid metabolite (StagX1-acid) through cleavage of the ethyl ester group. We identified carboxylesterase 1 (CES1) as the primary enzyme responsible for this conversion. Notably, cells expressing CES1 are sensitive to StagX1, whereas CES1-deficient cells show minimal response, indicating that metabolic activation is required for its activity. In contrast, StagX1-acid is metabolically stable. These findings suggest that StagX1 functions as a prodrug that is enzymatically converted to its active metabolite, StagX1-acid, within cells. This metabolic conversion likely underlies its mechanism of action and contributes to its selective anticancer activity in Ewing sarcoma. Our findings provide insight into the metabolism of StagX1 and the role of CES1 in mediating its effects and demonstrate that StagX1 is a promising compound with growth inhibitory effects in CES1 positive Ewing sarcoma cells.

PMID 42668658
Read full article →
PubMedJournal of chromatography. A2026-08-30

Automated miniaturized LLE-GC-MS/MS for the analysis of EPA 8270 SVOCs and multi-class pesticides in water using ethyl acetate.

Feo Maria Luisa ML, Benedetti Paolo P, Zanaboni Moira M, Tofful Luca L et al.

The determination of trace-level semi-volatile organic compounds (SVOCs) following EPA Method 8270 traditionally relies on manual liquid-liquid extraction (LLE) using large volumes of dichloromethane (DCM). However, recent 2024 TSCA regulations restricting DCM due to human health risks necessitate sustainable analytical alternatives. This study presents a fully automated, miniaturized LLE (micro-LLE) method for 170 analytes including EPA 8270 targets and multi-class pesticides (organochlorine (OCPs), organophosphorus (OPPs) and organonitrogen (ONPs) pesticides and pyrethroids). The workflow utilizes a TriPlus RSH SMART autosampler to integrate standard preparation, surrogate spiking, and extraction with on-line GC-MS/MS injection. Ethyl acetate was validated as a "green" alternative to DCM, with a 1:1 NaCl:MgSO₄ salt mixture optimizing the salting-out effect. This procedure achieved a tenfold enrichment factor using only 1.5 mL of solvent for 10 mL of sample. Method validation showed excellent linearity (R2> 0.995 for 70% of analytes) and precision (RSD < 15%). Method limits of quantification (MLOQs) between 0.05 and 10 µg/L meet stringent regulatory requirements. The method's robustness was confirmed through real-world Saharan deposition samples, identifying high levels of Phenothrin (211 ppb) and Endosulfan ether (140 ppb). This robotic workflow provides a high-throughput, sustainable solution for modern environmental monitoring.

PMID 42669230
Read full article →
PubMedJournal of nutritional science and vitaminology2026-08-30

Bio-Guided Fractionation of Cardamom Ethyl Acetate Fraction Promotes Glucose Uptake via GLUT4 Translocation through Insulin Signaling Pathway in the Skeletal Muscle.

Fang Liyuan L, Hironao Ken-Yu KY, Ashida Hitoshi H, Yamashita Yoko Y

Regulation of skeletal muscle glucose uptake is an effective strategy for reducing postprandial hyperglycemia and improving whole-body glucose homeostasis in the management of type 2 diabetes. The present study investigated that cardamom enhances glucose uptake in skeletal muscle in vitro and improves glucose tolerance in vivo. Bioactivity-guided fractionation of cardamom identified an ethyl acetate fraction (Fr. A) and its subfraction (Fr. A-i) as potent stimulators of glucose uptake in L6 myotubes. Both fractions significantly promoted glucose uptake by enhancing glucose transporter type 4 (GLUT4) translocation to the plasma membrane. Mechanistic investigations revealed activation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway, accompanied by increased phosphorylation of Akt substrate of 160 kDa (AS160), a key regulator of GLUT4 vesicle trafficking, while no significant changes were observed in insulin receptor substrate-1 (IRS-1) or AMP-activated protein kinase (AMPK) phosphorylation. Fr. A induced a more pronounced effect on AS160 phosphorylation and was therefore selected for further evaluation. The antihyperglycemic potential of Fr. A was assessed in ICR mice using an oral glucose tolerance test. Oral administration of Fr. A (1 and 10 mg/kg body weight) significantly improved glucose tolerance and alleviated postprandial hyperglycemia. Cardamom in skeletal muscle and highlights its potential as a natural therapeutic candidate for the management of postprandial hyperglycemia.

PMID 42669532
Read full article →
PubMedFood chemistry: X2026-08-30

Analysis of characteristic flavor compounds in coffee peels subjected to different thermal processing treatments based on GC-IMS and HS-SPME-GC-MS combined with chemical pattern recognition.

Meng Congyan C, Wu Jie J, Yan Chunrong C, Wei Jianqiang J et al.

This study investigated the effects of microwave thermal processing treatment (MD) and hot-air thermal processing treatment (HAD) on the volatile flavor compounds of coffee peel, using sun-dried (SG) samples as the control. GC-IMS and HS-SPME-GC-MS were combined with multivariate analyses (PCA and PLS-DA) and ROAV evaluation. A total of 62 and 56 volatile organic compounds (VOCs) were tentatively identified by GC-IMS and GC-MS, respectively, with ketones, aldehydes, alcohols, and esters representing the predominant classes. The two analytical methods exhibited complementary detection capabilities. PCA and PLS-DA clearly differentiated the three thermal drying treatments. Aroma-related compounds (VIP > 1 and ROAV ≥ 1) included 2-furanmethanethiol, 3-methylbutanal, (E)-2-decenal, ethyl heptanoate, hexanal, benzyl alcohol, linalool and β-ionone. Based on the nine core coffee flavor categories, SG exhibited a complex aroma profile characterized by herbal/vegetable, fruity, and nutty/cocoa notes; HAD was distinguished by highly pronounced floral notes; whereas MD presented both floral and roasted characteristics. The integrated analytical strategy effectively discriminated among different thermal processing treatments and identified putative aroma markers, which require further validation through olfactometry or sensory evaluation. This study provides a scientific basis for elucidating the flavor profile of coffee peel and supports the further development of coffee cascara tea products.

PMID 42668484
Read full article →
PubMedDrug development and industrial pharmacy2026-08-30

Development of Extended-Release Oral Dosage Forms of Salbutamol Sulfate Using the Hot-Melt Extrusion Manufacturing Technique.

Ramadan Banan B, Al-Zoubi Nizar N, Migdadi Eman E, AlSuwais Alia Kh AK et al.

To fabricate and characterize extrudable polymeric matrices using a combination of ethyl cellulose (EC) and two different grades of hydroxypropyl cellulose (HPC) that can provide sustained drug release of the model drug salbutamol sulfate. Implementation of the Hot-Melt Extrusion (HME) technique in the fabrication of polymeric combinations that will provide ready-to-use matrices for sustained release dosage forms. Two formulation groups were developed; each with six formulations. The first group contained EC: HPC 370,000 ratios ranging from 55.52:13.8% to 6.9:62.46%, respectively. The second group contained EC: HPC 80,000 ranging from 59.4:10% to 9.4:60%, respectively. The release profiles were determined via in vitro studies to assess the ability of matrices to prolong salbutamol release. Solid-state characterization was also performed on the raw material and representative extrudates formulations using differential scanning calorimetry (DSC) and X-ray powder diffraction (XRPD) and polarized light microscopy (PLM). The first group formulations exhibited prolonged drug release profiles that accelerated progressively as the level of HPC 370,000 increased. In contrast, the second group formulations exhibited a noticeably faster release, demonstrating that HPC 80,000 can effectively accelerate drug release through enhanced matrix erosion and water penetration. DSC and XRPD revealed that the model drug remained in its stable crystalline state even after thermal processing via HME. PLM further confirmed drug crystallinity within the extrudates. EC-HPC matrices successfully demonstrated the feasibility of using HME to prepare sustained-release matrices for salbutamol sulfate with the ability to tune drug release by varying polymer grade and ratio.

PMID 42669207
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about ethyl icosapentate